Editorial
Accepted on 29 Sep 2025
Editorial: Novel Therapeutic Strategies for Pancreatic Cancer: From Mechanisms to Clinical Translation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1705678
Type at least 3 characters
1,100 articles
Correction
Published on 29 Sep 2025
Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1682157
- 466 views
Review
Accepted on 26 Sep 2025
Overcoming Cancer Drug Resistance: Insights into Apoptotic Pathway Modulation by Plant based Nanoparticle and Natural Products
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1677380
- 313 views
Original Research
Published on 26 Sep 2025
Andrographolide suppresses chondrosarcoma cell migration and invasion by inhibiting the PI3K/Akt/mTOR signaling pathway and activating autophagy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1622666
- 1,585 views
Data Report
Published on 25 Sep 2025
An analysis of FDA drug approvals for oncological hematological malignancies in relation to companion diagnostics
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1635491
- 1,726 views
Case Report
Accepted on 24 Sep 2025
Case Report: Bevacizumab-Induced Renal-limited TMA and FSGS-like lesions in a Kidney Transplant Recipient
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1638274
- 290 views
Editorial
Published on 24 Sep 2025
Editorial: Head and neck squamous cell carcinoma: navigating the dawn of personalized medicine
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1684617
- 968 views
Editorial
Published on 24 Sep 2025
Editorial: Immune checkpoints regulatory mechanisms and immunotherapy strategies in gastrointestinal tumors
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1697974
- 1,216 views
Review
Accepted on 22 Sep 2025
The Role of Cytostatic in Oxidative Stress Reactions
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1667522
- 273 views
Correction
Accepted on 18 Sep 2025
Correction: Chorordin-like 1 Inhibits Pancreatic Cancer Cell Migration and Invasion: Involvement of the BMP4/SMAD Pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1705973
- 713 views
Review
Published on 17 Sep 2025
Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1592995
- 780 views
Original Research
Published on 05 Sep 2025
Osthole suppresses prostate cancer progression by modulating PRLR and the JAK2/STAT3 signaling axis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1630181
- 909 views
Original Research
Published on 03 Sep 2025
Oleanolic acid alleviates ovarian cancer by regulating the miR-122/PDK4 axis to induce autophagy and inhibit glycolysis in vivo and in vitro
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1670758
- 1,183 views
Original Research
Published on 01 Sep 2025
Effects of parthenolide on amino acid metabolism and oxidative stress in lung adenocarcinoma based on quantitative proteomic analysis, targeted amino acid metabolomics, network pharmacology, and experimental validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1642866
- 957 views
Original Research
Published on 01 Sep 2025
Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1542792
- 1,047 views
Original Research
Published on 29 Aug 2025
Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2025.1608451
- 1,229 views